Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors-Reference-Cited by-同舟云学术

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors

Published:2018-11-15 Issue:7 Volume:27 Page:2569-2577
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Abboud Camille N.,Lang Nicole,Fung Henry,Lammerich Andreas,Buchner Anton,Liu Patrick,Mueller Udo,Pettengell Ruth,Diel Ingo J.,Link Hartmut,Pathak Ashutosh

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-018-4522-5.pdf

Reference17 articles.

1. Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C (2013) Study design: two long-term observational studies of the biosimilar filgrastim Nivestim (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. BMC Cancer 13:547. https://doi.org/10.1186/1471-2407-13-547

2. National Comprehensive Cancer Network (2016) Clinical practice guidelines in oncology. Myeloid growth factors. Version 2.2016

3. Neupogen® (filgrastim) [prescribing information] (2016) Amgen, Inc., Thousand Oaks, CA

4. Pettengell R, Bias P, Mueller U, Lang N (2016) Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Support Care Cancer 24(6):2677–2684. https://doi.org/10.1007/s00520-015-3057-2

5. Granix® (tbo-filgrastim) [prescribing information] (2017) Teva Pharmaceuticals USA, Inc., North Wales, PA

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Capillary Leak Syndrome (SCLS) Presentation in Patients Receiving Anti-cancer Treatments;Cureus;2023-04-30

2. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience;BioDrugs;2022-05

3. Anticancer Drug-Induced Capillary Leak Syndrome;Kidney International Reports;2022-05

4. A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects;Drugs in R&D;2022-01-06

5. Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China;Medicine;2021-12-23